Study on the correlation between IDH gene mutation status in gliomas and metabolic parameters in 18F-FDG PET/CT
Lei Zeng, Ling Jiang, Tieying Ning, Yuanyuan Zhao, Yongyi Zhang, Junchen ZhangAim
To explore the correlation between isocitrate dehydrogenase (IDH) mutation status and 18 F-deoxyglucose ( 18 F-FDG) PET/computed tomography (CT) metabolic parameters in gliomas, and screen imaging biomarkers for preoperative prediction of IDH genotype.
Methods
Clinical and preoperative PET/CT data of 85 pathologically confirmed glioma patients were retrospectively analyzed, including 34 IDH-mutant and 51 IDH-wild-type cases. Lesion maximum standard uptake value (SUV max ), SUV max T/C (lesion-to-contralateral cortex) and SUV max T/W (lesion-to-contralateral white matter) were measured. Intergroup differences were compared via one-way analysis of variance, and receiver operating characteristic curves were applied to assess the predictive efficacy of significant parameters.
Results
All three metabolic indices were markedly elevated in IDH-wild-type tumors: SUV
max
(11.77 ± 5.94 vs. 9.46 ± 3.30;
Conclusion
IDH-wild-type gliomas present stronger glycolytic metabolism. 18 F-FDG PET/CT-derived SUV max , SUV max T/C, and SUV max T/W allow noninvasive preoperative evaluation of IDH status, with normalized ratio parameters demonstrating better diagnostic stability. Higher metabolic heterogeneity exists in IDH-wild-type gliomas.